Maria Beatrice Saccardo

Entrectinib, a Pan–TRK, ROS1, and ALK Inhibitor with Activity in Multiple Molecularly Defined Cancer Indications

Elena Ardini, Maria Menichincheri, Patrizia Banfi et al. · Molecular Cancer Therapeutics · 2016 · 312 citations · Full text

Medicine, Oncology, Pharmacology +17

Discovery of Entrectinib: A New 3-Aminoindazole As a Potent Anaplastic Lymphoma Kinase (ALK), c-ros Oncogene 1 Kinase (ROS1), and Pan-Tropomyosin Receptor Kinases (Pan-TRKs) inhibitor

Maria Menichincheri, Elena Ardini, Paola Magnaghi et al. · Journal of Medicinal Chemistry · 2016 · 298 citations · Full text

Medicine, Oncology, Pharmacology +17

Crystal Structures of Anaplastic Lymphoma Kinase in Complex with ATP Competitive Inhibitors

R Bossi, Maria Beatrice Saccardo, Elena Ardini et al. · Biochemistry · 2010 · 167 citations

Life Sciences, Molecular Biology, Oncology +17

The TPM3‐NTRK1 rearrangement is a recurring event in colorectal carcinoma and is associated with tumor sensitivity to TRKA kinase inhibition

Elena Ardini, Roberta Bosotti, Andrea Borgia et al. · Molecular Oncology · 2014 · 153 citations · Full text

Medicine, Cancer Biology, Oncology +17

Effects of switching from an AChE inhibitor to a dual AChE-BuChE inhibitor in patients with Alzheimer's disease

Luisa Bartorelli, C Giraldi, Maria Beatrice Saccardo et al. · Current Medical Research and Opinion · 2005 · 77 citations

Medicine, Geriatric Medicine, Geriatrics +16